A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma

A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma

Bibliographic Details
Main Authors:	Yashiro, M, Nishii, T, Hasegawa, T, Matsuzaki, T, Morisaki, T, Fukuoka, T, Hirakawa, K
Format:	Online
Language:	English
Published:	Nature Publishing Group 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833223/

Similar Items

An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells
by: Yashiro, M, et al.
Published: (2011)

Comparative Proteomics Analysis of Gastric Cancer Stem Cells
by: Morisaki, Tamami, et al.
Published: (2014)

Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer
by: Wang, Lin, et al.
Published: (2013)

Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia
by: Hirakawa, Toshiki, et al.
Published: (2016)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
by: Park, Chi Hoon, et al.
Published: (2016)

c-Met inhibitors
by: Mughal, Anum, et al.
Published: (2013)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
by: Jardim, Denis L. Fontes, et al.
Published: (2014)

Isothiocyanatostilbenes as novel c-Met inhibitors
by: Gray, Alana L., et al.
Published: (2015)

Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma
by: Wu, Ju-gang, et al.
Published: (2014)

Upregulation of cancer-associated myofibroblasts by TGF-β from scirrhous gastric carcinoma cells
by: Fuyuhiro, Y, et al.
Published: (2011)

Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study
by: Ogawa, Kohei, et al.
Published: (2012)

CD133 Is a Useful Surrogate Marker for Predicting Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer
by: Aomatsu, Naoki, et al.
Published: (2012)

Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
by: Aomatsu, Naoki, et al.
Published: (2014)

Gastric cancer--the recognition of a chemosensitive tumour.
by: Cunningham, D.
Published: (1988)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
by: Liuting Yang, et al.
Published: (2018-04-01)

Bone marrow-derived stromal cells are associated with gastric cancer progression
by: Kasashima, H, et al.
Published: (2015)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
by: Quackenbush, Kevin S., et al.
Published: (2016)

Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts
by: LIU, KAI, et al.
Published: (2015)

Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors
by: Yamaguchi, Hideki, et al.
Published: (2014)

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities
by: Wang, Ying, et al.
Published: (2016)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
by: Venepalli, Neeta K., et al.
Published: (2013)

Expression of c-met gene in invasive ductal carcinomas
by: Park, CH, et al.
Published: (2005)

Resistance to the c-Met inhibitor KRC-108 induces the epithelial transition of gastric cancer cells
by: KIM, DONG CHUL, et al.
Published: (2016)

Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery
by: Nasu, Kaei, et al.
Published: (2011)

Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery
by: Kaei Nasu, et al.
Published: (2011-01-01)

Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery
by: Hisashi Narahara, et al.
Published: (2011-03-01)

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities
by: Waterhouse, Dawn N., et al.
Published: (2014)

Successful combination chemotherapy with irinotecan hydrochloride and cisplatin for primary gastric small cell carcinoma: report of a case
by: Funahashi, Hitoshi, et al.
Published: (2013)

The spectrum of chemosensitivity of two human pancreatic carcinoma xenografts.
by: Courtenay, V. D., et al.
Published: (1982)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
by: Matsuoka, Tasuku, et al.
Published: (2014)

The outcome of surgical treatment for elderly patients with gastric carcinoma
by: Sakurai, Katsunobu, et al.
Published: (2015)

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
by: Shuch, Brian, et al.
Published: (2015)

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
by: Satoh, Taroh, et al.
Published: (2014)

PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma
by: Matsuoka, T, et al.
Published: (2012)

The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays
by: Sotoudeh, Kambiz, et al.
Published: (2012)

Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors
by: Yıldız, Yetkin, et al.
Published: (2016)

Silencing of XB130 Is Associated with Both the Prognosis and Chemosensitivity of Gastric Cancer
by: Shi, Min, et al.
Published: (2012)

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
by: Masuda, N., et al.
Published: (1993)

Irinotecan-Induced Dysarthria
by: Dressel, Albertine J., et al.
Published: (2012)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
by: Tang, Chad, et al.
Published: (2013)